Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
Tobias Dittrich,
Axel Benner,
Christoph Kimmich,
Fabian aus dem Siepen,
Kaya Veelken,
Arnt V. Kristen,
Tilmann Bochtler,
Hugo A. Katus,
Carsten Müller-Tidow,
Ute Hegenbart,
Stefan O. Schönland
Affiliations
Tobias Dittrich
Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital;Amyloidosis Center, Heidelberg University Hospital;Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, Heidelberg University Hospital
Axel Benner
Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg
Christoph Kimmich
Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital;Amyloidosis Center, Heidelberg University Hospital
Fabian aus dem Siepen
Amyloidosis Center, Heidelberg University Hospital;Department of Internal Medicine III, Division of Cardiology, Heidelberg University Hospital, Germany
Kaya Veelken
Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital;Amyloidosis Center, Heidelberg University Hospital
Arnt V. Kristen
Amyloidosis Center, Heidelberg University Hospital;Department of Internal Medicine III, Division of Cardiology, Heidelberg University Hospital, Germany
Tilmann Bochtler
Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital;Amyloidosis Center, Heidelberg University Hospital;Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, Heidelberg University Hospital
Hugo A. Katus
Department of Internal Medicine III, Division of Cardiology, Heidelberg University Hospital, Germany
Carsten Müller-Tidow
Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital;Amyloidosis Center, Heidelberg University Hospital
Ute Hegenbart
Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital;Amyloidosis Center, Heidelberg University Hospital
Stefan O. Schönland
Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital;Amyloidosis Center, Heidelberg University Hospital
Systemic light chain amyloidosis is a rare and life-threatening disorder, for which accurate risk stratification is crucial. Current cardiac staging systems (MAYO2004, MAYO3b, and MAYO2012) are mainly based on biomarkers, which have uncertain reliability in the context of atrial fibrillation, arrhythmia or pacemaker stimulation as well as renal insufficiency. We compared the performance of the established staging systems with particular regard to these comorbidities in 1,224 patients with systemic light chain amyloidosis diagnosed at our center from July 2002 until March 2017. We first characterized the subsets with an estimated glomerular filtration rate
